Curing inflammatory diseases using phosphorous dendrimers

Area of Science:

• Nanotechnology Approaches to Biology
• Nanoscale Systems in Biology
• Therapeutic Approaches and Drug Discovery
• Emerging Technologies
• Nanomedicine for Neurological Disease

Background:

• Water-soluble phosphorous dendrimers exhibit diverse biological properties.
• First-generation phosphorous dendrimers with azabisphosphonate terminal functions stimulate the human immune system ex vivo.
• These dendrimers are rapidly internalized by monocytes, inducing anti-inflammatory activation.

Purpose of the Study:

• To investigate the immunomodulatory and anti-inflammatory effects of azabisphosphonate-functionalized phosphorous dendrimers.
• To evaluate the in vivo efficacy of these dendrimers in animal models of inflammatory diseases and myeloid leukemia.
• To assess the hematological and immunological safety of azabisphosphonate-dendrimers in preclinical studies.

Main Methods:

• Ex vivo studies involving monocyte internalization, differentiation inhibition, and immune cell proliferation assays.
• In vivo testing in animal models for chronic/acute inflammatory diseases (multiple sclerosis, rheumatoid arthritis, uveitis, psoriasis) and myeloid leukemia.
• Hematological safety assessment in mice and non-human primates, including biochemical, hematological, and immunological parameter monitoring.

Main Results:

• Azabisphosphonate dendrimers inhibit monocyte differentiation into osteoclasts and dendritic cell maturation.
• They suppress proinflammatory CD4+ T lymphocyte proliferation and induce natural killer cell expansion ex vivo.
• In vivo studies demonstrated efficacy against inflammatory diseases and myeloid leukemia with no observed hematological toxicity in mice or non-human primates.

Conclusions:

• Azabisphosphonate-functionalized phosphorous dendrimers possess significant immunomodulatory and anti-inflammatory properties.
• These dendrimers show promise as therapeutic agents for various inflammatory conditions and myeloid leukemia.
• Preclinical safety assessments confirm a favorable safety profile in both murine and primate models.